Fifty-seven gynecological malignancy patients who received chemotherapy at the Department of Obstetrics and Gynecology, Nanning Fourth People’s Hospital from January 2022 to December 2025 were selected. InclusionCriteria: 1) Pathologically confirmed diagnosis of gynecological malignancies such as cervical cancer, ovarian cancer; 2) Completion of at least one cycle of chemotherapy; 3) Complete clinical data (including blood routine tests, liver and kidney function tests, HIV test results); 4) HIV-positive patients received standard HAART for ≥3 months [6]. GroupingMethod: Patients were divided into an HIV-positive group (n = 44) and an HIV-negative group (n = 13) based on confirmed HIV infection status (laboratory HIV antibody / test results). The background color code in the data table (yellow for HIV-negative, white for HIV-positive) was only used for data management and not as a grouping basis.

The following data were collected via the hospital’s electronic medical record system: age, disease type, clinical stage, chemotherapy regimen, number of chemotherapy cycles, duration of HIV infection (positive group), HAART regimen (positive group); white blood cell (WBC) count, neutrophil (NEUT) count, hemoglobin (Hb), platelet (PLT) count, CD4+ T-lymphocyte count (HIV-positive group) before and after chemotherapy; neutropenia (graded according to CTCAE 5.0), gastrointestinal reactions (nausea, vomiting, diarrhea), and infectious complications (pneumonia, urinary tract infection, etc.).

Data analysis was performed using SPSS 30.0 software. Continuous variables were expressed as mean ± standard deviation ( x ¯ ± s ). Inter-group comparisons were made using the independent samples t-test, and intra-group comparisons before and after chemotherapy were made using the paired t-test. Categorical variables were expressed as count (percentage), and comparisons were made using the χ² test or Fisher’s exact test when expected frequencies were less than 5. A P-value < 0.05 was considered statistically significant.

There were no statistically significant differences in baseline characteristics such as age, disease distribution, clinical stage, and chemotherapy regimen between the two groups (P > 0.05), indicating comparability (Table 1). In the HIV-positive group, the average duration of infection was 5.2 ± 3.8 years, 93.2% (41/44) of patients had a viral load <50 copies/mL, and the main HAART regimens were zidovudine + lamivudine + nevirapine (34.1%) and efavirenz + tenofovir + lamivudine (27.3%).3 cases (6.8%) had a viral load ≥50 copies/mL, of which 2 developed mild gastrointestinal reactions and 1 had grade I neutropenia, with no severe infections or chemotherapy interruptions reported.

3.2.1. Changes in Blood Routine Indicators

WBC, neutrophil, hemoglobin, and platelet counts decreased after chemotherapy in both groups compared to pre-chemotherapy levels, but the magnitudes of decrease were not statistically significantly different between groups (P > 0.05). Details are shown in Table 2. The decrease in WBC was 1.89 ± 1.32 × 10⁹/L in the HIV-positive group vs 1.93 ± 1.28 × 10⁹/L in the HIV-negative group (P = 0.921); the decrease in neutrophil count was 1.76 ± 1.15 × 10⁹/L vs 1.81 ± 1.09 × 10⁹/L (P = 0.887); the decrease in hemoglobin was 15.8 ± 8.3 g/L vs 14.9 ± 7.6 g/L (P = 0.743); the decrease in platelet count was 27 ± 18 × 10⁹/L vs 25 ± 16 × 10⁹/L (P = 0.785).

Table 1. Comparison of baseline characteristics between groups.

Table 2. Comparison of blood routine indicators before and after chemotherapy between groups ( x ¯ ± s ).

3.2.2. Changes in Immune Function Indicators

In the HIV-positive group, the CD4+ T-lymphocyte count significantly decreased after chemotherapy (482 ± 295 vs 395 ± 241 cells/μL, t = 3.215, P = 0.002). 86.4% (38/44) of patients maintained a CD4+ count above 300 cells/μL. The HIV-negative group did not undergo CD4+ T-lymphocyte testing as it is not a routine clinical indicator for immunocompetent individuals without HIV infection. Their total lymphocyte counts showed no significant change before and after chemotherapy (2.35 ± 0.87 vs 2.28 ± 0.81 × 109/L, P = 0.653), indicating no obvious systemic immune suppression induced by chemotherapy.

There were no statistically significant differences in the incidence of chemotherapy-related complications between the two groups (P > 0.05). Details are shown in Table 3. The incidence of grade III-IV neutropenia was 13.6% (6/44) in the HIV-positive group vs 7.7% (1/13) in the HIV-negative group (P = 0.682). Gastrointestinal reactions were predominantly mild to moderate, with incidences of 84.1% (37/44) and 84.6% (11/13) respectively (P = 0.967). Infectious complications in the HIV-positive group included 2 cases of pneumonia and 2 cases of urinary tract infection; the HIV-negative group had 1 case of urinary tract infection (P = 0.885). Liver and kidney function abnormalities were mild in both groups, with an incidence of 11.4% (5/44) in the HIV-positive group vs 7.7% (1/13) in the HIV-negative group (P = 0.738).

Table 3. Comparison of Chemotherapy-Related complications between groups (n, %).

This study showed no significant differences between the two groups in the magnitude of post-chemotherapy decreases in blood routine indicators or the incidence of grade III-IV toxicities, consistent with the results of a multicenter study by Huang etal. [7]. That study included 32 HIV-positive and 45 HIV-negative cervical cancer patients and found no significant differences in the incidence of grade III-IV neutropenia (12.5% vs 9.8%) or chemotherapy delay rates (15.6% vs 13.3%).

From a mechanistic perspective, standard HAART is crucial for HIV-positive patients to achieve good chemotherapy tolerance. In this study, 93.2% of HIV-positive patients had a viral load <50 copies/mL, and the baseline CD4+ count was 482 ± 295 cells/μL, approaching normal immune levels [8], laying the foundation for chemotherapy tolerance.

Despite the overall good chemotherapy tolerance in HIV-positive patients, the significant post-chemotherapy decrease in CD4+ count (average decrease of 87 cells/μL) highlights the need for enhanced immune function monitoring. Studies show that HIV-infected individuals with a CD4+ count <200 cells/μL have a significantly increased risk of chemotherapy-related infections [9]. Therefore, the following is recommended: monitor CD4+ count every 2 chemotherapy cycles; consider prophylactic use of cotrimoxazole if CD4+ count falls below 300 cells/μL; and avoid using chemotherapy regimens with strong bone marrow toxicity when CD4+ count is below 200 cells/μL.

It should be noted that the small sample size of the control group (n = 13) may lead to a risk of Type II error. Statistical power analysis indicated that the power of this study for the primary outcome (incidence of grade III-IV neutropenia) was approximately 65% (α = 0.05), which is lower than the ideal level (80%). Thus, the conclusion of “no significant difference between groups” may be influenced by insufficient statistical power. Future studies with an expanded control group sample size are needed to further verify the reliability of the findings [10].

The “comparison of immune function” in this study is strictly limited to general blood routine indicators (white blood cell, neutrophil, and lymphocyte counts). Since CD4+ T-lymphocyte count was not measured in the control group, targeted comparison of immune function subsets could not be performed. This limitation in the study scope should be clearly stated to avoid overinterpretation of the results.